Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Captain Wild Bill Wichrowski has been open with Deadliest Catch fans about his cancer battle. Here's the latest update.

Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

His wife convinced him to go for a "man check" which eventually led to a prostate cancer diagnosis, a move from New Zealand to Australia and a place in a world-first medical trial. Subscribe for FREE ...

A ground-breaking treatment for cancer described by doctors as being like a ‘heat seeking missile’ has boosted survival rates and quality of life for patients with fewer side effects.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.